@article{8c1da13017a84a8194a73b042a27eb2b,
title = "Introduction to the Reports from the Insights in Pediatric CAR T-cell Immunotherapy: Recent Advances and Future Directions (INSPIRED) Symposium",
keywords = "Acute lymphoblastic leukemia, Children and young adults, Chimeric antigen receptor T-cells, Immunotherapy, Relapse, Salvage therapy",
author = "Liora Schultz and Elad Jacoby and Lamble, \{Adam J.\} and Maude, \{Shannon L.\} and McNerney, \{Kevin O.\} and Amy Moskop and Myers, \{Regina M.\} and Pulsipher, \{Michael A.\} and Shah, \{Nirali N.\}",
note = "Funding Information: Financial disclosure: Support by National Institutes of Health Grant UG1HL069254 and a grant from the St. Baldrick's Foundation Johnny Christopher Fund. Funding Information: The authors acknowledge the speakers and chairs of the INSPIRED Symposium ( https://ncifrederick.cancer.gov/events/conferences/INSPIRED2023 ) for their contributions, and also thank the Pediatric Transplantation and Cellular Therapy Consortium (PTCTC) and the National Cancer Institute Intramural Research Program for their support of this meeting. Funding Information: The authors acknowledge the speakers and chairs of the INSPIRED Symposium (https://ncifrederick.cancer.gov/events/conferences/INSPIRED2023) for their contributions, and also thank the Pediatric Transplantation and Cellular Therapy Consortium (PTCTC) and the National Cancer Institute Intramural Research Program for their support of this meeting. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government. N.N.S is supported by the Intramural Program of the NCI (ZIA BC 011823). Financial disclosure: Support by National Institutes of Health Grant UG1HL069254 and a grant from the St. Baldrick's Foundation Johnny Christopher Fund. Conflict of interest statement: L.M.S. reports serving on advisory boards for Novartis and Cargo Therapeutics. E.J. reports receiving honoraria from Novartis. S.L.M reports clinical trial support: Novartis, Wugen; consulting, advisory boards, or study steering committee: Novartis, and patent pending and licensed to Novartis Pharmaceuticals for PCT/US2017/044425: Combination Therapies for Car and PD-1 Inhibitors. M.A.P. reports serving on advisory boards for Cargo Therapeutics, Novartis, Gentibio, Bluebird, Vertex, Medexus, and Equillium; receiving study support from Adaptive and Miltenyi. N.N.S. reports attending advisory board meetings for Sobi and VOR. Authorship statement: N.N.S drafted the first version of this manuscript, however all authors provided substantial edits and input into the concept and manuscript writing. All authors provided final approval of manuscript and all authors are accountable for all aspects of work. Financial disclosure: See Acknowledgments on page XXXX. Funding Information: The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government. N.N.S is supported by the Intramural Program of the NCI (ZIA BC 011823). ",
year = "2023",
month = oct,
doi = "10.1016/j.jtct.2023.07.009",
language = "אנגלית",
volume = "29",
pages = "592--593",
journal = "Transplantation and Cellular Therapy",
issn = "2666-6375",
publisher = "Elsevier",
number = "10",
}
SDG 3 Good Health and Well-being